Status:
UNKNOWN
A Registered Cohort Study of Inflammatory Demyelination Disease
Lead Sponsor:
Ning Wang, MD., PhD.
Conditions:
Demyelinating Autoimmune Diseases, CNS
Eligibility:
All Genders
Brief Summary
This study will provide further insights into the natural course of Inflammatory demyelination disease including clinical features，progression, related antibody spectrum and drug treatment effect
Eligibility Criteria
Inclusion
- Outpatient or inpatient
- Meet the diagnostic criteria of Inflammatory Demyelination Disease.
- Voluntary participation and informed consent signed by the applicant or his/her family.
Exclusion
- Severe complications
- Poor prognosis (\<1 year survival)
- Severe mental disorder and inability to cooperate with the examination.
Key Trial Info
Start Date :
May 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04386018
Start Date
May 15 2020
End Date
April 1 2025
Last Update
November 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology,First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005